Resource Summary Report

Generated by RRID on Sep 2, 2026

Panc 02.03

RRID:CVCL_1633
Type: Cell Line

Proper Citation

RRID:CVCL_1633

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1633

Proper Citation: RRID:CVCL_1633

Description: Cell line Panc 02.03 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Pancreatic adenocarcinoma

Defining Citation: PMID:9612602, PMID:18000365, PMID:20037478, PMID:22460905, PMID:22585861, PMID:25167228, PMID:25485619, PMID:25877200, PMID:26216984, PMID:26589293, PMID:27259358, PMID:27397505, PMID:28196595, PMID:29444439, PMID:30894373, PMID:30971826, PMID:31068700, PMID:31978347, PMID:35839778

Comments: Population: Caucasian., From: Johns Hopkins University School of Medicine; Baltimore; USA., Part of: NCI RAS program mutant KRAS cell line panel., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: Panc 02.03

Synonyms: PANC-02-03, Panc_02_03, Panc02.03, Panc 2.03, Panc2.03, Panc2_03, PANC 203, Panc203, PANC203, PANC0203, Panc0203

Cross References: CLO:CLO_0008374, EFO:EFO_0006466, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-2553, BioGRID_ORCS_Cell_line:491, BioSample:SAMN03473181, BioSample:SAMN10987714, cancercelllines:CVCL_1633, Cell_Model_Passport:SIDM01139, ChEMBL-

Cells:CHEMBL3307761, ChEMBL-Targets:CHEMBL612584, Cosmic:2009528, Cosmic:2434088, Cosmic-CLP:1298475, DepMap:ACH-000042, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:1298475, GEO:GSM206527, GEO:GSM621891, GEO:GSM887494, GEO:GSM888576, GEO:GSM1024405, GEO:GSM1374810, GEO:GSM1670331, IARC_TP53:28226, LiGeA:CCLE_407, LINCS_LDP:LCL-1739, PharmacoDB:Panc02_03_1239_2019, PRIDE:PXD003198, PRIDE:PXD030304, Progenetix:CVCL_1633, PubChem_Cell_line:CVCL_1633, Wikidata:Q54937512

ID: CVCL_1633

Record Creation Time: 20220427T221408+0000

Record Last Update: 20260829T235541+0000

Ratings and Alerts

No rating or validation information has been found for Panc 02.03.

No alerts have been found for Panc 02.03.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 15 mentions in open access literature.

Listed below are recent publications. The full list is available at RRID .

Assi M, et al. (2026) Extracellular matrix sensing regulates intratumoral heterogeneity of autophagic flux. Cell, 189(6), 1731.

Zhang H, et al. (2026) Programmable iPSC-derived CAR-NK vesicles remodel the immune microenvironment and eradicate tumors. Cell reports. Medicine, 7(2), 102545.

Ning W, et al. (2026) A bispecific nanobody-drug conjugate targeting TROP2 and c-Met for low-concentration, single-dose treatment of pancreatic cancer. Cell reports. Medicine, 7(4), 102688.

Gong D, et al. (2026) GLIS3 marks a neural-like progenitor cell state that drives metastasis in pancreatic ductal adenocarcinoma. Cell reports, 45(5), 117314.

Bandi DSR, et al. (2026) ADT-030, a novel PDE10 inhibitor, demonstrates potent antitumor activity in pancreatic ductal adenocarcinoma. bioRxiv : the preprint server for biology.

Lyubetskaya A, et al. (2026) In situ multi-modal characterization of pancreatic cancer reveals tumor cell identity as a defining factor of the surrounding microenvironment. Cell

reports, 45(1), 116827.

Xie L, et al. (2026) Preclinical Characterization and Clinical Activity of RNK08954, a Highly Selective and Orally Bioavailable KRASG12D Inhibitor. Cancer discovery, 16(5), 895.

Zhang Y, et al. (2026) SERPINA3 mediates liver cancer cells escape from chemotherapy-induced neutrophil extracellular trap killing. Cell reports, 45(2), 116956.

Gong D, et al. (2025) Integrated spatial morpho-transcriptomics predicts functional traits in pancreatic cancer. Science advances, 11(42), eadx0632.

Yuan L, et al. (2025) Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degrader of the Nuclear Pore Complex. Cancer discovery, 15(12), 2505.

Wang S, et al. (2025) IFN-??-driven UBE2D3 upregulation impairs antigen presentation pathways and anti-tumor immunity in pancreatic cancer. Nature communications, 16(1), 10733.

Oles AR, et al. (2025) MyoD is essential in rhabdomyosarcoma by promoting survival through differentiation and CYLD. iScience, 28(8), 113149.

Qian J, et al. (2025) A CXCR4 partial agonist improves immunotherapy by targeting immunosuppressive neutrophils and cancer-driven granulopoiesis. Cancer cell, 43(8), 1512.

Abt ER, et al. (2022) Reprogramming of nucleotide metabolism by interferon confers dependence on the replication stress response pathway in pancreatic cancer cells. Cell reports, 38(2), 110236.

Banh RS, et al. (2020) Neurons Release Serine to Support mRNA Translation in Pancreatic Cancer. Cell, 183(5), 1202.